New Oral Alzheimer's Drug Obtains FDA Fast Track Qualification

Article source: Medical Rubik's Cube Info

Author: Sunshine

On December 22, Vivoryon announced that the FDA has granted its oral small molecule drug varoglutamstat (PQ912, SIM0408) fast track qualification for the treatment of early Alzheimer’s disease (AD)

Simcere Pharmaceuticals reached a $500 million cooperation with Vivoryon in June this year, and obtained the development and commercialization of two types of neurotoxic amyloid N3pE (pGlu-Abeta) in Greater China, including Varoglutamstat.

Alzheimer's disease (AD) is the most common type of senile dementia.

Varoglutamstat is an oral small-molecule inhibitor targeting glutaminyl peptide cyclotransferase (QPCT).

Varoglutamstat can prevent the production of N3pE amyloid by inhibiting QPCT and its isoenzymes

Neurotoxic amyloid N3pE can trigger AD-related pathological pathways

Varoglutamstat's pharmacy, toxicology, main pharmacodynamics and other properties have been verified by preclinical studies

Currently, there is no drug with the same target on the market globally